

## 7. Literaturverzeichnis

1. Labrie F, Simard J, Luu The V et al. Expression of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) and 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) in adipose tissue. *Int J Obes* 1991; 15 Suppl 2:91-99.
2. Labrie F, Luu-The V, Lin SX et al. Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. *J Mol Endocrin* 2000; 25(1).
3. Penning TM. Molecular endocrinology of hydroxysteroid dehydrogenases. *Endocrine Reviews* 1997; 18(3):281-305.
4. Carlstedt-Duke J. Glucocorticoid receptor beta: view II. *Trends Endocrin Metabol* 1999; 10(8):339-342.
5. Vottero A, Chrousos GP. Glucocorticoid receptor  $\beta$ : View I. *Trends Endocrinol Metab* 1999; 10:333-338.
6. Rabbitt EH, Lavery GG, Walker EA, Cooper MS, Stewart PM, Hewison M. Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. *FASEB J* 2002; 16(1):36-44.
7. Rabbitt EH, Ayuk J, Boelaert K et al. Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. *Oncogene* 2003; 22(11):1663-1667.
8. Rabbitt EH, Gittoes NJ, Stewart PM, Hewison M. 11beta-Hydroxysteroid dehydrogenases, cell proliferation and malignancy. *J Steroid Biochem Mol Biol* 2003; 85(2-5):415-421.
9. Souque A, Fagart J, Couette B et al. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. *Endocrinology* 1995; 136(12):5651-5658.
10. Rupprecht R, Reul JM, van Steensel B et al. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. *Eur J Pharmacol* 1993; 247(2):145-54.
11. Evans RM. The steroid and thyroid hormone receptor superfamily. *Science* 1988; 240(4854):889-895.

12. Arriza JL, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. *Science* 1987; 237(4812):268-275.
13. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Annu Rev Biochem* 1994; 63:451-86:451-486.
14. Ylikomi T, Wurtz JM, Syvälä H et al. Reappraisal of the role of heat shock proteins as regulators of steroid receptor activity. *Crit Rev Biochem Mol Biol* 1998; 33:437-466.
15. Zennaro MC, Borensztein P, Soubrier F, Armanini D, Corvol P. The enigma of pseudohypoaldosteronism. *Steroids* 1994; 59(2):96-99.
16. Geller DS, Rodriguez-Soriano J, Vallo BA et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. *Nat Genet* 1998; 19(3):279-281.
17. Geller DS, Farhi A, Pinkerton N et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. *Science* 2000; 289(7July):119-123.
18. Couette B, Jalaguier S, Hellal-Levy C et al. Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor [In Process Citation]. *Mol Endocrinol* 1998; 12(6):855-863.
19. Lombes M, Farman N, Oblin ME et al. Immunohistochemical localization of renal mineralocorticoid receptor by using an anti-idiotypic antibody that is an internal image of aldosterone. *Proc Natl Acad Sci U S A* 1990; 87(3):1086-1088.
20. Sasano H, Fukushima K, Sasaki I, Matsuno S, Nagura H, Krozowski ZS. Immunolocalization of mineralocorticoid receptor in human kidney, pancreas, salivary, mammary and sweat glands: a light and electron microscopic immunohistochemical study. *J Endocrinol* 1992; 132(2):305-310.
21. Smith DF, Toft DO. Steroid receptors and their associated proteins. *Molec Endocrin* 1993; 7(1):4-11.
22. Fukushima DK, Levin J, Kream J et al. Effect of flutamide on cortisol metabolism. *J Clin Endocrinol Metab* 1978; 47(4):788-791.
23. Rundle SE, Funder JW, Lakshmi V, Monder C. The intrarenal localization of mineralocorticoid receptors and 11 beta-dehydrogenase: immunocytochemical studies. *Endocrinology* 1989; 125(3):1700-1704.
24. Rundle SE, Smith AI, Stockman D, Funder JW. Immunocytochemical demonstration of mineralocorticoid receptors in rat and human kidney. *J Steroid Biochem* 1989; 33(6):1235-1242.

25. Hirasawa G, Sasano H, Takahashi K-I et al. Colocalization of 11beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. *J Clin Endocrinol Metab* 1997; 82(11):3859-3863.
26. Garty H, Palmer LG. Epithelial sodium channels: function, structure, and regulation. *Physiol Rev* 1997; 77(2):359-396.
27. Garty H. Regulation of the epithelial Na<sup>+</sup> channel by aldosterone: open questions and emerging answers. *Kidney Int* 2000; 57(4):1270-1276.
28. Pearce D, Bhargava A, Cole TJ. Aldosterone: its receptor, target genes, and actions. *Vitam Horm* 2003; 66:29-76.
29. Rogerson FM, Brennan FE, Fuller PJ. Dissecting mineralocorticoid receptor structure and function. *J Steroid Biochem Mol Biol* 2003; 85(2-5):389-396.
30. Stockand JD. New ideas about aldosterone signaling in epithelia. *Am J Physiol Renal Physiol* 2002; 282(4):F559-F576.
31. Chen SY, Bhargava A, Mastroberardino L et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. *Proc Natl Acad Sci U S A* 1999; 96(5):2514-2519.
32. Conn JW, Knopf RF. Clinical characteristics of primary aldosteronism from analysis of 145 cases. *Am J Surg* 1964; 107:159-172.
33. Stokes J, Noble J, Brett L et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. *Invest Ophthalmol Vis Sci* 2000; 41(7):1629-1638.
34. Mirshahi M, Mirshahi S, Golestaneh N et al. Demonstration of the mineralocorticoid hormone receptor and action in human leukemic cell lines. *Leukemia* 2000; 14:1097-1104.
35. Watzka M, Beyenburg S, Blumcke I, Elger CE, Bidlingmaier F, Stoffel-Wagner B. Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus. *Neurosci Lett* 2000; 290(2):121-124.
36. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. *Circ Res* 1992; 71(3):503-510.
37. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. *Hypertension* 2000; 35(5):1078-1084.
38. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. *J Am Soc Nephrol* 2003; 14(9):2395-2401.

39. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003; 348(14):1309-1321.
40. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999; 341(10):709-717.
41. McDermott M, Latif S, Morris DJ. The metabolism of aldosterone in kidney. *J Steroid Biochem* 1983; 19:1205-1211.
42. Morris DJ, McDermott MJ, Freiburger M, Latif SA, Pacholski M, Brem AS. The effects of antimineralocorticoids on synthesis of aldosterone metabolites in target tissues. *J Steroid Biochem* 1986; 24(1):341-344.
43. Morris DJ. The biological significance of reduced metabolites of aldosterone. *Hum Pathol* 1979; 10(2):128-31.
44. Reilly RF, Ellison DH. Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy. *Physiol Rev* 2000; 80(1):277-313.
45. Lifton RP. Molecular genetics of human blood pressure variation. *Science* 1996; 272(5262):676-680.
46. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. *Nat Genet* 1996; 13(2):183-188.
47. Hansson JH, Nelson-Williams C, Suzuki H et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. *Nat Genet* 1995; 11(1):76-82.
48. Mulders SM, Bichet DG, Rijss JP et al. An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex. *J Clin Invest* 1998; 102(1):57-66.
49. Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG. Genetic disorders of renal electrolyte transport. *N Engl J Med* 1999; 340(15):1177-1187.
50. Loffing J, Kaissling B. Sodium and calcium transport pathways along the mammalian distal nephron: from rabbit to human. *Am J Physiol Renal Physiol* 2003; 284(4):F628-F643.
51. Reilly RF, Shugrue CA, Lattanzi D, Biemesderfer D. Immunolocalization of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger in rabbit kidney. *Am J Physiol* 1993; 265(2 Pt 2):F327-F332.

52. Nielsen S, Kwon TH, Frokiaer J, Knepper MA. Key Roles of Renal Aquaporins in Water Balance and Water-Balance Disorders. *News Physiol Sci* 2000; 15:136-143.
53. Canessa CM, Schild L, Buell G et al. Amiloride-sensitive epithelial Na<sup>+</sup> channel is made of three homologous subunits. *Nature* 1994; 367(6462):463-467.
54. Snyder PM. The epithelial Na<sup>+</sup> channel: cell surface insertion and retrieval in Na<sup>+</sup> homeostasis and hypertension. *Endocr Rev* 2002; 23(2):258-275.
55. McDonald FJ, Price MP, Snyder PM, Welsh MJ. Cloning and expression of the beta- and gamma-subunits of the human epithelial sodium channel. *Am J Physiol* 1995; 268(5 Pt 1):C1157-C1163.
56. Shimkets RA, Warnock DG, Bositis CM et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. *Cell* 1994; 79(3):407-414.
57. Chang SS, Grunder S, Hanukoglu A et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. *Nat Genet* 1996; 12(3):248-253.
58. Iwai N, Baba S, Mannami T, Ogihara T, Ogata J. Association of a sodium channel alpha subunit promoter variant with blood pressure. *J Am Soc Nephrol* 2002; 13(1):80-85.
59. Renard S, Voilley N, Bassilana F, Lazdunski M, Barbry P. Localization and regulation by steroids of the alpha, beta and gamma subunits of the amiloride-sensitive Na<sup>+</sup> channel in colon, lung and kidney. *Pflugers Arch* 1995; 430(3):299-307.
60. Escoubet B, Coureau C, Bonvalet JP, Farman N. Noncoordinate regulation of epithelial Na channel and Na pump subunit mRNAs in kidney and colon by aldosterone. *Am J Physiol* 1997; 272(5 Pt 1):C1482-C1491.
61. MacDonald P, MacKenzie S, Ramage L, Seckl J, Brown RW. Corticosteroid regulation of amiloride-sensitive sodium-channel subunit mRNA expression in mouse kidney. *J Endocrin* 2000; 165:25-37.
62. Lingueglia E, Renard S, Waldmann R et al. Different homologous subunits of the amiloride-sensitive Na<sup>+</sup> channel are differently regulated by aldosterone. *J Biol Chem* 1994; 269(19):13736-13739.
63. Fuller PJ, Brennan FE, Burgess JS. Acute differential regulation by corticosteroids of epithelial sodium channel subunit and Nedd4 mRNA levels in the distal colon. *Pflugers Arch* 2000; 441(1):94-101.

64. Itani OA, Auerbach SD, Husted RF et al. Glucocorticoid-stimulated lung epithelial Na(+) transport is associated with regulated ENaC and sgk1 expression. *Am J Physiol Lung Cell Mol Physiol* 2002; 282(4):L631-L641.
65. Tchepichev S, Ueda J, Canessa C, Rossier BC, O'Brodivich H. Lung epithelial Na channel subunits are differentially regulated during development and by steroids. *Am J Physiol* 1995; 269(3 Pt 1):C805-C812.
66. Quinkler M, Bujalska IJ, Kaur K et al. Androgen receptor-mediated regulation of the alpha-subunit of the epithelial sodium channel ( $\alpha$ ENaC) in human kidney. *JASN* 2004; submitted.
67. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. *Science* 1988; 242(4878):583-585.
68. Edwards CR, Stewart PM, Burt D et al. Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. *Lancet* 1988; 2(8618):986-989.
69. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 $\beta$ -hydroxysteroid dehydrogenase type 2 enzyme. *Molecular and Cellular Endocrinology* 1994; 105:R11-R17.
70. Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. *J Clin Endocrinol Metab* 1994; 79(2):480-484.
71. Whorwood CB, Mason JI, Ricketts ML, Howie AJ, Stewart PM. Detection of human 11 $\beta$ -hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts. *Molecular and Cellular Endocrinology* 1995; 110:R7-R12.
72. Funder JW. How can aldosterone act as a mineralocorticoid? *Endocr Res* 1989; 15(1-2):227-238.
73. Ballard PL, Carter JP, Graham BS, Baxter JD. A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. *J Clin Endocrinol Metab* 1975; 41(2):290-304.
74. Monder C, Lakshmi V. Evidence for kinetically distinct forms of corticosteroid 11 beta-dehydrogenase in rat liver microsomes. *J Steroid Biochem* 1989; 32(1A):77-83.
75. Whorwood CB, Sheppard MC, Stewart PM. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. *Endocrinology* 1993; 132(6):2287-2292.

76. Quinkler M, Oelkers W, Diederich S. Clinical implications of glucocorticoid metabolism by 11beta-hydroxysteroid dehydrogenases in target tissues. *Eur J Endocrinol* 2001; 144(2):87-97.
77. Tortorella C, Aragona F, Nussdorfer GG. In vivo evidence that human adrenal glands possess 11beta- hydroxysteroid dehydrogenase activity. *Life Sci* 1999; 65(26):2823-2827.
78. Draper N, Walker EA, Bujalska IJ et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. *Nat Genet* 2003; 34(4):434-439.
79. Meulenber EP, Hofman JA. The effect of pretreatment of saliva on steroid hormone concentrations. *J Clin Chem Clin Biochem* 1990; 28(12):923-928.
80. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. *Clin Sci (Colch )* 1999; 96(5):513-523.
81. Walker EA, Stewart PM. 11beta-hydroxysteroid dehydrogenase: unexpected connections. *Trends Endocrinol Metab* 2003; 14(7):334-339.
82. Tomlinson JW, Walker EA, Bujalska IJ et al. 11{beta}-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. *Endocr Rev* 2004.
83. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? *Lancet* 1997; 349(9060):1210-1213.
84. Stewart PM, Boulton A, Kumar S, Clark PMS, Shackleton CHL. Cortisol metabolism in human obesity: impaired cortisone to cortisol conversion in subjects with central adiposity. *J Clin Endocrin Metabol* 1999; 84(3):1022-1027.
85. Tomlinson JW, Moore J, Cooper MS et al. Regulation of Expression of 11beta-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines. *Endocrinology* 2001; 142(5):1982-1989.
86. Edwards CR, Walker BR, Benediktsson R, Seckl JR. Congenital and acquired syndromes of apparent mineralocorticoid excess. *J Steroid Biochem Mol Biol* 1993; 45(1-3):1-5.
87. New MI, Levine LS, Biglieri EG, Pareira J, Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. *J Clin Endocrinol Metab* 1977; 44(5):924-933.
88. Werder E, Zachmann M, Vollmin JA, Veyrat R, Prader A. Unusual steroid excretion in a child with low renin hypertension. *Research in steroids* 1974; 6:385-389.

89. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. *J Clin Invest* 1988; 82(1):340-349.
90. Quinkler M, Bappal B, Draper N et al. Molecular basis for the Apparent Mineralocorticoid Excess Syndrome in the Oman population. *Mol Cell Endocrinol* 2004; 217(1-2):143-149.
91. Stewart PM, Krozowski ZS. 11 beta-Hydroxysteroid dehydrogenase. *Vitam Horm* 1999; 57:249-324.
92. Quinkler M, Oelkers W, Diederich S. In Vivo Measurement of Renal 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Activity. *J Clin Endocrinol Metab* 2000; 85(12):4921-4922.
93. Palermo M, Shackleton CHL, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11 $\beta$ -hydroxysteroid dehydrogenase activity in man. *Clin Endocrinol (Oxf)* 1996; 45:605-611.
94. Palermo M, Cossu M, Shackleton CHL. Cure of Apparent Mineralocorticoid Excess by Kidney Transplantation. *N Engl J Med* 1998; 329(24):1787-1788.
95. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. *J Clin Endocrinol Metab* 2003; 88(6):2384-2392.
96. Mune T, Rogerson FM, Nikkilä H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 $\beta$ -hydroxysteroid dehydrogenase. *Nature Genetics* 1995; 10:394-399.
97. Stewart PM, Krozowski ZS, Gupta A et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 $\beta$ -hydroxysteroid dehydrogenase type 2 gene. *Lancet* 1996; 347:88-91.
98. White PC, Mune T, Agarwal AK. 11beta-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess. *Endocrine Reviews* 1997; 18(1):135-156.
99. Wilson RC, Harbison MD, Krozowski ZS et al. Several homozygous mutations in the gene for 11 $\beta$ -hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. *J Clin Endocrinol Metab* 1995; 80:3145-3150.
100. White PC, Mune T, Agarwal AK. 11 $\beta$ -hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. *Endocr Rev* 1997; 18:135-156.
101. Nunez BS, Rogerson FM, Mune T et al. Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. *Hypertension* 1999; 34(4 Pt 1):638-642.



102. Li A, Li KX, Marui S et al. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. *J Hypertens* 1997; 15(12 Pt 1):1397-1402.
103. Molhuysen JA, Gerbrandy J, De Vries LA et al. A liquorice extract with Deoxycortone-like action. *Lancet* 1950;(Sept.23):381-386.
104. Armanini D, Karbowski I, Funder JW. Affinity of liquorice derivatives for mineralocorticoid and glucocorticoid receptors. *Clin Endocrinol Oxf* 1983; 19(5):609-612.
105. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CR. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. *Endocrinology* 1989; 125(2):1046-1053.
106. Kageyama Y, Suzuki H, Saruta T. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney. *J Endocrinol* 1992; 135(1):147-152.
107. Bernardi M, D'Intino PE, Trevisani F et al. Effects of prolonged ingestion of graded doses of licorice by healthy volunteers. *Life Sci* 1994; 55(11):863-872.
108. Epstein MT, Espiner EA, Donald RA, Hughes H, Cowles RJ, Lun S. Licorice raises urinary cortisol in man. *J Clin Endocrinol Metab* 1978; 47(2):397-400.
109. MacKenzie MA, Hoefnagels WH, Jansen RW, Benraad TJ, Kloppenborg PW. The influence of glycyrrhetic acid on plasma cortisol and cortisone in healthy young volunteers. *J Clin Endocrinol Metab* 1990; 70(6):1637-1643.
110. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. *Lancet* 1987; 2(8563):821-824.
111. Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM. Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. *Clin Endocrinol Oxf* 1986; 24(6):699-713.
112. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CR. Mineralocorticoid excess and inhibition of 11 beta- hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. *Clin Endocrinol Oxf* 1992; 37:483-492.
113. Ulick S, Wang JZ, Blumenfeld JD, Pickering TG. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. *J Clin Endocrinol Metab* 1992; 74(5):963-967.
114. Eisenschmid B, Heilmann P, Oelkers W, Rejaibi R, Schoneshofer M. 20-Dihydroisomers of cortisol and cortisone in human urine: excretion rates under

- different physiological conditions. J Clin Chem Clin Biochem 1987; 25(6):345-349.
115. Diederich S, Quinkler M, Möbius K, Heilmann P, Schöneshöfer M, Oelkers W. Effects of ACTH on renal and hepatic 11beta-hydroxysteroid-dehydrogenase in the guinea pig. Exp Clin Endocrinol 1996; 104 (Suppl.1):112.
  116. Walker BR, Stewart PM, Shackleton CH, Padfield PL, Edwards CR. Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol Oxf 1993; 39(2):221-227.
  117. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Evidence of coexisting changes in 11 $\beta$ -hydroxysteroid dehydrogenase and 5 $\beta$ -reductase activity in subjects with untreated essential hypertension. Hypertension 1995; 25:67-70.
  118. Watson B, Jr., Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension 1996; 28(3):478-482.
  119. Smolenicka Z, Bach E, Schaer A et al. A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene. J Clin Endocrinol Metab 1998; 83(5):1814-1817.
  120. Brand E, Kato N, Chatelain N et al. Structural analysis and evaluation of the 11 $\beta$ -hydroxysteroid dehydrogenase type 2 (*11 $\beta$ -HSD2*) gene in human essential hypertension. J Hypertens 1998; 16:1627-1633.
  121. Smith RE, Little PJ, Maguire JA, Stein-Oakley AN, Krozowski ZS. Vascular localization of the 11 $\beta$ -hydroxysteroid dehydrogenase type II enzyme. Clin Exp Pharmacol Physiol 1996; 23(6-7):549-551.
  122. Teelucksingh S, Mackie AD, Burt D, McIntyre MA, Brett L, Edwards C. Potentiation of hydrocortisone activity in skin by glycyrrhetic acid. Lancet 1990; 335(8697):1060-1063.
  123. Hatakeyama H, Inaba S, Takeda R, Miyamori I. 11beta-Hydroxysteroid dehydrogenase in human vascular cells. Kidney Int 2000; 57(4):1352-1357.
  124. Souness GW, Brem AS, Morris DJ. 11beta-Hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids 2002; 67(3-4):195-201.
  125. Kenouch S, Lombes M, Delahaye F, Eugene E, Bonvalet J-P, Farman N. Human skin as target for aldosterone: Coexpression of mineralocorticoid receptors and 11 $\beta$ -hydroxysteroid dehydrogenase. J Clin Endocrinol Metab 1994; 79:1334-1341.

126. Walker BR, Connacher AA, Webb DJ, Edwards CR. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. *Clin Sci* 1992; 83(2):171-178.
127. Walker BR, Williams BC, Edwards CRW. Regulation of 11 $\beta$ -hydroxysteroid dehydrogenase activity by the hypothalamic-pituitary-adrenal axis in the rat. *J Endocrinol* 1994; 141:467-472.
128. Whitworth JA, Stewart PM, Burt D, Atherden SM, Edwards CR. The kidney is the major site of cortisone production in man. *Clin Endocrinol Oxf* 1989; 31(3):355-361.
129. Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. *J Clin Endocrinol Metab* 1985; 60(5):848-854.
130. Srivastava LS, Werk EE, Jr., Thrasher K et al. Plasma cortisone concentration as measured by radioimmunoassay. *J Clin Endocrinol Metab* 1973; 36(5):937-943.
131. Quinkler M, Zehnder D, Lepenies J et al. Expression of renal 11 $\beta$ -hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. *Eur J Endocrinol* 2005; submitted.
132. Vogt B, Dick B, N'Gankam V, Frey FJ, Frey BM. Reduced 11 $\beta$ -hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome. *J Clin Endocrinol Metab* 1999; 84:811-814.
133. Quinkler M, Diederich S, Bahr V, Oelkers W. The role of progesterone metabolism and androgen synthesis in renal blood pressure regulation. *Horm Metab Res* 2004; 36(6):381-386.
134. Quinkler M, Meyer B, Bumke-Vogt C et al. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor. *Eur J Endocrinol* 2002; 146(6):789-799.
135. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. *Steroids* 1996; 61(4):166-71.
136. Wilson M, Morganti AA, Zervoudakis I et al. Blood pressure, the renin-aldosterone system and sex steroids throughout normal pregnancy. *American J Medicine* 1980; 68:97-104.
137. Murakami T, Watanabe Ogura E, Tanaka Y, Yamamoto M. High blood pressure lowered by pregnancy. *Lancet* 2000; 356(9246):1980.
138. Landau RL, Bergenstal DM, Lugibihl K, Kascht ME. The metabolic effects of progesterone in man. *J Clin Endocrinol Metab* 1955; 15:1194-1215.

139. Landau RL, Lugibihl K, Bergenstal DM, Dimick DF. The metabolic effects of progesterone in man: Dose response relationships. *J Lab Clin Med* 1957; 50:613-620.
140. Laidlaw JC, Ruse JL, Gornall AG. The influence of estrogen and progesterone on aldosterone excretion. *J Clin Endocr Metabol* 1962; 22:161-171.
141. Oparil S, Ehrlich EN, Lindheimer MD. Effect of progesterone on renal sodium handling in man: relation to aldosterone excretion and plasma renin activity. *Clin Sci Mol Med* 1975; 49(2):139-147.
142. Oelkers W, Schöneshöfer M, Blümel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. *J Clin Endocrinol Metab* 1974; 39:882-890.
143. Quinkler M, Kosmale B, Bähr V, Oelkers W, Diederich S. Evidence for isoforms of 11beta-hydroxysteroid dehydrogenase in the liver and kidney of the guinea pig. *J Endocrinol* 1997; 153:291-298.
144. Agarwal AK, Monder C, Eckstein B, White PC. Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. *J Biol Chem* 1989; 264(32):18939-18943.
145. Rajan V, Chapman KE, Lyons V et al. Cloning, sequencing and tissue-distribution of mouse 11 $\beta$ -hydroxysteroid dehydrogenase-1 cDNA. *J Steroid Biochem Mol Biol* 1995; 52:141-147.
146. Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. *J Biol Chem* 1991; 266:16653-16658.
147. Maser E, Bannenberg G. 11 beta-hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds. *Biochem Pharmacol* 1994; 47(10):1805-1812.
148. Ge RS, Gao HB, Nacharaju VL, Gunsalus GL, Hardy MP. Identification of a kinetically distinct activity of 11 $\beta$ -hydroxysteroid dehydrogenase in rat Leydig cells. *Endocrinology* 1997; 138:2435-2442.
149. Gomez-Sanchez EP, Ganjam V, Chen YJ et al. The sheep kidney contains a novel unidirectional, high affinity NADP<sup>+</sup>-dependent 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ -HSD- 3). *Steroids* 1997; 62:444-450.
150. Michael AE, Evagelatou M, Norgate DP et al. Isoforms of 11beta-hydroxysteroid dehydrogenase in human granulosa-lutein cells. *Mol Cell Endocrinol* 1997; 132:43-52.

151. Pu X, Yang K. Guinea pig 11beta-hydroxysteroid dehydrogenase type 1: primary structure and catalytic properties. *Steroids* 2000; 65:148-156.
152. Shafqat N, Elleby B, Svensson S et al. Comparative Enzymology of 11beta - Hydroxysteroid Dehydrogenase Type 1 from Glucocorticoid Resistant (Guinea Pig) Versus Sensitive (Human) Species. *J Biol Chem* 2003; 278(3):2030-2035.
153. Abel SM, Back DJ, Maggs JL, Park BK. Cortisol metabolism by human liver in vitro--IV. Metabolism of 9 alpha-fluorocortisol by human liver microsomes and cytosol. *J Steroid Biochem Mol Biol* 1993; 46(6):833-839.
154. Abel SM, Back DJ, Maggs JL, Park BK. Cortisol metabolism in vitro--II. Species difference. *J Steroid Biochem Mol Biol* 1993; 45:445-453.
155. Abel SM, Maggs JL, Back DJ, Park BK. Cortisol metabolism by human liver in vitro--I. Metabolite identification and inter-individual variability. *J Steroid Biochem Mol Biol* 1992; 43:713-719.
156. Quinkler M, Troeger H, Eigendorff E et al. Enhanced 11beta-hydroxysteroid dehydrogenase type 1 activity in stress adaptation in the guinea pig. *J Endocrinol* 2003; 176(2):185-192.
157. Claman HN. Corticosteroids and lymphoid cells. *N Engl J Med* 1972; 287(8):388-397.
158. Kraft N, Hodgson AJ, Funder JW. Glucocorticoid receptor and effector mechanisms: a comparison of the corticosensitive mouse with the corticoresistant guinea pig. *Endocrinology* 1979; 104(2):344-349.
159. Quirk SJ, Slattery J, Funder JW. 11 beta-hydroxysteroid dehydrogenase activity in the mammary gland. *J Steroid Biochem* 1990; 35(5):623-625.
160. Handoko K, Yang K, Strutt B, Khalil W, Killinger D. Insulin attenuates the stimulatory effects of tumor necrosis factor alpha on 11beta-hydroxysteroid dehydrogenase 1 in human adipose stromal cells. *J Steroid Biochem Mol Biol* 2000; 72(3-4):163-168.
161. Friedberg M, Zoumakis E, Hiroi N, Bader T, Chrousos GP, Hochberg Z. Modulation of 11beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. *J Clin Endocrinol Metab* 2003; 88(1):385-393.
162. Masuzaki H, Paterson J, Shinyama H et al. A Transgenic Model of Visceral Obesity and the Metabolic Syndrome. *Science* 2001 2001; 294(5549):2166-2170.
163. Diederich S, Grossmann C, Hanke B et al. In the search for specific inhibitors of human 11beta- hydroxysteroid dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I. *European J Endocrinology* 1999;(in press).

164. Ulick S, Levine LS, Gunczler P et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. *J Clin Endocrinol Metab* 1979; 49(5):757-764.
165. Ponz de Leon M, Loria P, Carulli N, Murphy GM, Dowling RH. Intestinal solubilization, absorption, pharmacokinetics and bioavailability of chenodeoxycholic acid. *Eur J Clin Invest* 1980; 10(4):261-271.
166. Morita H, Zhou MY, Foecking MF, Gomez-Sanchez EP, Cozza EN, Gomez-Sanchez CE. 11 $\beta$ -Hydroxysteroid dehydrogenase type 2 complementary deoxyribonucleic acid stably transfected into Chinese hamster ovary cells: Specific inhibition by 11 $\alpha$ -hydroxyprogesterone. *Endocrinology* 1996; 137:2308-2314.
167. Souness GW, Latif SA, Lorenzo JL, Morris DJ. 11 $\alpha$ - and 11 $\beta$ -hydroxyprogesterone, potent inhibitors of 11 $\beta$ -hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat. *Endocrinology* 1995; 136:1809-1812.
168. Odermatt A, Dick B, Arnold P et al. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. *J Clin Endocrinol Metab* 2001; 86(3):1247-1252.
169. Christy NP, Laragh JH. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. *N Engl J Med* 1961; 265(22):1083-1088.
170. Horio S, Funahashi H, Mizuno S. [Plasma steroid hormones in Cushing's syndrome: their relation to cause and clinical manifestations (author's transl)]. *Nippon Naibunpi Gakkai Zasshi* 1981; 57(5):807-825.
171. Kater CE, Biglieri EG, Brust N, Chang B, Hirai J. Regulation of the mineralocorticoid hormones in adrenocortical disorders with adrenocorticotropin excess. *Clin Exp Hypertens A* 1982; 4(9-10):1749-1758.
172. Whitworth JA, Saines D, Thatcher R, Butkus A, Scoggins BA. Blood pressure and metabolic effects of ACTH in normotensive and hypertensive man. *Clin Exp Hypertens A* 1983; 5(4):501-522.
173. Vaitukaitis JL, Dale SL, Melby JC. Role of ACTH in the secretion of free dehydroepiandrosterone and its sulfate ester in man. *J Clin Endocrinol Metab* 1969; 29(11):1443-1447.
174. Monder C, White PC. 11 beta-hydroxysteroid dehydrogenase. *Vitam Horm* 1993; 47:187-271.
175. Biglieri EG, Arteaga E, Kater CE. Effect of ACTH on aldosterone and other mineralocorticoid hormones. *Ann N Y Acad Sci* 1987; 512:426-437.

176. Al-Saadi N, Diederich S, Oelkers W. A very high dose dexamethasone suppression test for differential diagnosis of Cushing's syndrome. *Clin Endocrinol (Oxf)* 1998; 48(1):45-51.
177. Mayenknecht J, Diederich S, Bahr V, Plockinger U, Oelkers W. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease [In Process Citation]. *J Clin Endocrinol Metab* 1998; 83(5):1558-1562.
178. Diederich S, Quinkler M, Miller K, Heilmann P, Schoeneshofer M, Oelkers W. Human kidney 11 $\beta$ -hydroxysteroid dehydrogenase: Regulation by adrenocorticotropin? *European Journal of Endocrinology* 1996; 134(3):301-307.
179. Agarwal AK, Giacchetti G, Lavery G et al. CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity. *Hypertension* 2000; 36(2):187-194.
180. Lovati E, Ferrari P, Dick B et al. Molecular basis of human salt sensitivity: The role of the 11 $\beta$ -hydroxysteroid dehydrogenase type 2. *J Clin Endocrinol Metab* 1999; 84:3745-3749.
181. Nienstedt W, Ojanotko A, Toivonen H. Metabolism of progesterone, 17-hydroxyprogesterone and deoxycorticosterone by human small intestine in vitro. *J Steroid Biochem* 1980; 13(12):1417-20.
182. Blom T, Ojanotko Harri A, Laine M, Huhtaniemi I. Metabolism of progesterone and testosterone in human parotid and submandibular salivary glands in vitro. *J Steroid Biochem Mol Biol* 1993; 44(1):69-76.
183. Ojanotko-Harri A. Metabolism of progesterone by healthy and inflamed human gingiva in vitro. *J Steroid Biochem* 1985; 23(6A):1031-1035.
184. Maeyama M, Ikemoto M. Progesterone metabolism by human fetal and placental tissues: interconversion of progesterone and 20- $\alpha$ -hydroxypregn-4-en-3-one in the feto-placental unit in vitro. *Endocrinol Jpn* 1967; 14(3):232-8.
185. Rupprecht R, Arriza JL, Spengler D et al. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. *Mol Endocrinol* 1993; 7(4):597-603.
186. Myles K, Funder JW. Progesterone binding to mineralocorticoid receptors: In vitro and in vivo studies. *Am J Physiol Endocrinol Metab* 1996; 270:E601-E607.
187. Buster JE, Chang RJ, Preston DL et al. Interrelationships of circulating maternal steroid concentrations in third trimester pregnancies. II. C18 and C19 steroids: estradiol, estriol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, delta 5-androstenediol, delta 4- androstenedione, testosterone, and dihydrotestosterone. *J Clin Endocrinol Metab* 1979; 48(1):139-142.

188. Pearson Murphy BE, Allison CM. Determination of progesterone and some of its neuroactive ring A- reduced metabolites in human serum. *J Steroid Biochem Mol Biol* 2000; 74:137-142.
189. Landau RL, Lugibihl K. Inhibition of the sodium-retaining influence of aldosterone by progesterone. *J Clin Endocrinol Metab* 1958; 18:1237-1245.
190. Winkel CA, Simpson ER, Milewich L, MacDonald PC. Deoxycorticosterone biosynthesis in human kidney: potential for formation of a potent mineralocorticosteroid in its site of action. *Proc Natl Acad Sci U S A* 1980; 77(12):7069-7073.
191. Winkel CA, Milewich L, Parker CR, Jr., Gant NF, Simpson ER, MacDonald PC. Conversion of plasma progesterone to deoxycorticosterone in men, nonpregnant and pregnant women, and adrenalectomized subjects. *J Clin Invest* 1980; 66(4):803-812.
192. Winkel CA, Casey ML, Simpson ER, MacDonald PC. Deoxycorticosterone biosynthesis from progesterone in kidney tissue of the human fetus. *J Clin Endocrinol Metab* 1981; 53(1):10-15.
193. Winkel CA, Parker CR, Jr., Simpson ER, MacDonald PC. Production rate of deoxycorticosterone in women during the follicular and luteal phases of the ovarian cycle: the role of extraadrenal 21-hydroxylation of circulating progesterone in deoxycorticosterone production. *J Clin Endocrinol Metab* 1980; 51(6):1354-1358.
194. Quinkler M, Johanssen S, Grossmann C et al. Progesterone metabolism in the human kidney and inhibition of 11beta- hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. *J Clin Endocrinol Metab* 1999; 84(11):4165-4171.
195. Quinkler M, Johanssen S, Bumke-Vogt C, Oelkers W, Bahr V, Diederich S. Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney. *Mol Cell Endocrinol* 2001; 171(1-2):21-4.
196. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. *J Clin Endocrinol Metab* 1981; 53(1):58-68.
197. Hanukoglu I. Steroidogenic enzymes: Structure, function, and role in regulation of steroid hormone biosynthesis. *J Steroid Biochem Mol Biol* 1992; 43(8):779-804.
198. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha- hydroxylase/17,20 lyase): similarity with the gene for P450c21. *DNA* 1987; 6(5):439-448.
199. Miller WL, Auchus RJ, Geller DH. The regulation of 17,20-lyase activity. *Steroids* 1997; 62:133-142.



200. Lachance Y, Luu-The V, Labrie C et al. Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5- delta 4-isomerase gene and its expression in mammalian cells [published erratum appears in J Biol Chem 1992 Feb 15;267(5):3551]. J Biol Chem 1990; 265(33):20469-20475.
201. Rheaume E, Lachance Y, Zhao HF et al. Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5- delta 4-isomerase in human adrenals and gonads. Mol Endocrinol 1991; 5:1147-1157.
202. Feltus FA, Groner B, Melner MH. Stat5-mediated regulation of the human type II 3 $\beta$ -hydroxysteroid dehydrogenase/Delta<sup>5</sup>-Delta<sup>4</sup> isomerase gene: Activation by prolactin. Mol Endocrinol 1999; 13:1084-1093.
203. Provost PR, Blomquist CH, Godin C et al. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3. Endocrinology 2000; 141(8):2786-2794.
204. Zhou Z, Shackleton CH, Pahwa S, White PC, Speiser PW. Prominent sex steroid metabolism in human lymphocytes. Mol Cell Endocrinol 1998; 138(1-2):61-69.
205. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrin Metabol 2000; 85(7):2519-2525.
206. McCartin S, Russell AJ, Fisher RA et al. Phenotypic variability and origins of mutations in the gene encoding 3beta-hydroxysteroid dehydrogenase type II. J Molec Endocrin 2000; 24:75-82.
207. Moisan AM, Ricketts ML, Tardy V et al. Commentary: New insight into the molecular basis of 3beta- hydroxysteroid dehydrogenase deficiency: Identification of eight mutations in the HSD3B2 gene: eleven patients from seven new families and comparison of the functional properties of twenty- five mutant enzymes. J Clin Endocrin Metabol 1999; 84:4410-4425.
208. Pirog EC, Collins DC. Metabolism of dihydrotestosterone in human liver: importance of 3alpha- and 3beta-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab 1999; 84(9):3217-21.
209. Leb CR, Hu F-Y, Murphy BEP. Metabolism of progesterone by human lymphocytes: production of neuroactive steroids. J Clin Endocrinol Metab 1997; 82(12):4064-4068.
210. Barker EV, Hume R, Hallas A, Coughtrie MWH. Dehydroepiandrosterone sulfotransferase in the developing human fetus: Quantitative biochemical and immunological characterization of the hepatic, renal, and adrenal enzymes. Endocrinology 1994; 134:982-989.

211. Martel C, Melner MH, Gagne D, Simard J, Labrie F. Widespread tissue distribution of steroid sulfatase, 3 beta- hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta- HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. *Mol Cell Endocrinol* 1994; 104(1):103-11.
212. DallaValle L, Belvedere P, Simontacchi C, Colombo L. Extraglandular hormonal steroidogenesis in aged rats. *J Steroid Biochem Mol Biol* 1992; 43(8):1095-1098.
213. Hatakeyama H, Miyamori I, Takeda Y, Yamamoto H, Mabuchi H. The expression of steroidogenic enzyme genes in human vascular cells. *Biochem Mol Biol Int* 1996; 40:639-645.
214. Silvestre JS, Robert V, Heymes C et al. Myocardial production of aldosterone and corticosterone in the rat - Physiological regulation. *J Biol Chem* 1998; 273:4883-4891.
215. Rudolph AE, Blasi ER, Delyani JA. Tissue-specific corticosteroidogenesis in the rat. *Mol Cell Endocrin* 2000; 165:221-224.
216. Mellon SH, Deschepper CF. Neurosteroid biosynthesis: Genes for adrenal steroidogenic enzymes are expressed in the brain. *Brain Res* 1993; 629:283-292.
217. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez Sanchez EP. Aldosterone Biosynthesis in the Rat Brain. *Endocrinology* 1997; 138(8):3369-3373.
218. Mahendroo MS, Cala KM, Landrum CP, Russell DW. Fetal death in mice lacking 5alpha reductase type 1 caused by estrogen excess. *Mol Endocrin* 1997; 11:917-927.
219. Mahendroo MS, Porter A, Russell DW, Word RA. The parturition defect in steroid 5alpha reductase type 1 knockout mice is due to impaired cervical ripening. *Mol Endocrin* 1999; 13:981-992.
220. Auchus RJ, Miller WL. Molecular modeling of human P450c17 (17alpha-hydroxylase / 17,20- Lyase): insights into reaction mechanism and effects of mutations. *Molec Endocrin* 1999; 13:1169-1182.
221. Zwain IH, Yen SSC. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. *Endocrinology* 1999; 140(8):3843-3852.
222. Vianello S, Waterman MR, Dalla Valle L, Colombo L. Developmentally regulated expression and activity of 17alpha- hydroxylase/C-17,20-lyase cytochrome P450 in rat liver. *Endocrinology* 1997; 138(8):3166-3174.
223. Compagnone NA, Bulfone A, Rubenstein JLR, Mellon SH. Steroidogenic enzyme P450c17 is expressed in the embryonic central nervous system. *Endocrinology* 1995; 136(11):5212-5223.

224. Swart P, Swart AC, Waterman MR, Estabrook RW, Mason JI. Progesterone 16 $\alpha$ -hydroxylase activity is catalyzed by human cytochrome P450 17 $\alpha$ -hydroxylase. *J Clin Endocrinol Metab* 1993; 77:98-102.
225. Lin D, Black SM, Nagahama Y, Miller WL. Steroid 17 $\alpha$ -hydroxylase and 17,20-lyase activities of P450c17: Contributions of serine106 and P450 reductase. *Endocrinology* 1993; 132(6):2498-2506.
226. Auchus RJ, Lee TC, Miller WL. Cytochrome b<sub>5</sub> augments the 17,20-lyase activity of human P450c17 without direct electron transfer. *J Biol Chem* 1998; 273(6):3158-3165.
227. Katagiri M, Kagawa N, Waterman MR. The role of cytochrome b<sub>5</sub> in the biosynthesis of androgens by human P450c17. *Archives of Biochemistry and Biophysics* 1995; 317:343-347.
228. Jenkins EP, Hsieh C-L, Milatovich A et al. Characterization and chromosomal mapping of human steroid 5 $\alpha$ -reductase gene and pseudogene and mapping of the mouse homologue. *Genomics* 1991; 11:1102-1112.
229. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5 $\alpha$ -reductase 2 gene in male pseudohermaphroditism. *Nature* 1991; 354:159-161.
230. Labrie F, Sugimoto Y, Luu-The V et al. Structure of human type II 5 $\alpha$ -reductase gene. *Endocrinology* 1992; 131(3):1571-1573.
231. MacDonald PC, Dombroski RA, Casey ML. Recurrent secretion of progesterone in large amounts: an endocrine/metabolic disorder unique to young women? *Endocr Rev* 1991; 12(4):372-401.
232. Concas A, Follesa P, Barbaccia ML, Purdy RH, Biggio G. Physiological modulation of GABA (A) receptor plasticity by progesterone metabolites. *Eur J Pharmacol* 1999; 375(1-3):225-235.
233. Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA, Seachrist JL. The 4-pregnene and 5 $\alpha$ -pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. *Cancer Research* 2000; 60(February 15):936-943.
234. Wiebe JP, Lewis MJ. Activity and expression of progesterone metabolizing 5 $\alpha$ -reductase, 20 $\alpha$ -hydroxysteroid oxidoreductase and 3 $\alpha$ -( $\beta$ )-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. *BMC Cancer* 2003; 3(1):9.
235. Suzuki T, Darnel AD, Akahira JI et al. 5 $\alpha$ -reductases in human breast carcinoma: possible modulator of in situ androgenic actions. *J Clin Endocrinol Metab* 2001; 86(5):2250-7.

236. Jez JM, Bennett MJ, Schlegel BP, Lewis M, Penning TM. Review Article: Comparative anatomy of the aldo-keto reductase superfamily. *J Biochem* 1997; 326:625-636.
237. Jez JM, Flynn TG, Penning TM. Commentary: A new nomenclature for the aldo-keto reductase superfamily. *Biochem Pharmacol* 1997; 54(6):639-647.
238. Penning TM. Molecular determinants of steroid recognition and catalysis in aldo-keto reductases. Lessons from 3 $\alpha$ -hydroxysteroid dehydrogenase. *J Ster Biochem Molec Biol* 1999; 69:211-225.
239. Penning TM, Burczynski ME, Jez JM et al. Human 3 $\alpha$ -hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. *Biochem J* 2000; 351(Pt 1):67-77.
240. Nishizawa M, Nakajima T, Yasuda K et al. Close kinship of human 20 $\alpha$ -hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. *Genes Cells* 2000; 5(2):111-125.
241. Bumke-Vogt C, Bahr V, Diederich S et al. Expression of the progesterone receptor and progesterone- metabolising enzymes in the female and male human kidney. *J Endocrinol* 2002; 175(2):349-364.
242. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 $\alpha$ -reductase isoenzyme expression. *J Clin Invest* 1993; 92:903-910.
243. Jez JM, Penning TM. Engineering steroid 5 $\beta$ -reductase activity into rat liver 3 $\alpha$ -hydroxysteroid dehydrogenase. *Biochemistry* 1998; 37:9695-9703.
244. Charbonneau A, The VL. Genomic organization of a human 5 $\beta$ -reductase and its pseudogene and substrate selectivity of the expressed enzyme. *Biochim Biophys Acta* 2001; 1517(2):228-35.
245. Pollow K, Lubbert H, Boquoi E, Pollow B. Progesterone metabolism in normal human endometrium during the menstrual cycle and in endometrial carcinoma. *J Clin Endocrinol Metab* 1975; 41(4):729-37.
246. Bird CE, Wiqvist N, Diczfalusy E, Solomon S. Metabolism of progesterone by perfused previable human fetus. *J Clin Endocrinol* 1966; 26:1144-1154.
247. Quinkler M, Bumke-Vogt C, Meyer B, Bahr V, Oelkers W, Diederich S. The human kidney is a progesterone-metabolizing and androgen-producing organ. *J Clin Endocrinol Metab* 2003; 88(6):2803-2809.

248. Chang C, Kokontis J. Identification of a new member of the steroid receptor super-family by cloning and sequence analysis. *Biochem Biophys Res Commun* 1988; 155(2):971-977.
249. Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. *Endocrinology* 1984; 114(6):2100-2106.
250. Sundaram K, Kumar N, Monder C, Bardin CW. Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens. *J Steroid Biochem Mol Biol* 1995; 53(1-6):253-257.
251. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. *Science* 1974; 186(4170):1213-1215.
252. Imperato-McGinley J, Peterson RE, Gautier T, Sturla E. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency. *N Engl J Med* 1979; 300(22):1233-1237.
253. Peterson RE, Imperato-McGinley J, Gautier T, Sturla E. Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. *Am J Med* 1977; 62(2):170-191.
254. French FS, Lubahn DB, Brown TR et al. Molecular basis of androgen insensitivity. *Recent Prog Horm Res* 1990; 46:1-38.
255. Nelson CC, Hendy SC, Shukin RJ et al. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: Evidence for differential steroid receptor response elements. *Mol Endocrinol* 1999; 13:2090-2107.
256. Hsiao PW, Thin TH, Lin DL, Chang C. Differential regulation of testosterone vs. 5alpha-dihydrotestosterone by selective androgen response elements. *Mol Cell Biochem* 2000; 206(1-2):169-175.
257. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. *Proc Natl Acad Sci U S A* 1998; 95(13):7379-7384.
258. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. *Mol Endocrinol* 1991; 5(12):1921-1930.
259. Adler AJ, Scheller A, Robins DM. The stringency and magnitude of androgen-specific gene activation are combinatorial functions of receptor and nonreceptor binding site sequences. *Mol Cell Biol* 1993; 13(10):6326-6335.

260. Ho KC, Marschke KB, Tan J, Power SG, Wilson EM, French FS. A complex response element in intron 1 of the androgen-regulated 20-kDa protein gene displays cell type-dependent androgen receptor specificity. *J Biol Chem* 1993; 268(36):27226-27235.
261. Avila DM, Fuqua SA, George FW, McPhaul MJ. Identification of genes expressed in the rat prostate that are modulated differently by castration and Finasteride treatment. *J Endocrinol* 1998; 159(3):403-411.
262. Harshfield GA, Alpert BS, Pulliam DA, Somes GW, Wilson DK. Ambulatory blood pressure recordings in children and adolescents. *Pediatrics* 1994; 94(2 Pt 1):180-184.
263. Bachmann H, Horacek U, Leowsky M, Hirche H. [Blood pressure in children and adolescents aged 4 to 18. Correlation of blood pressure values with age, sex, body height, body weight and skinfold thickness (Essen Blood Pressure Study)]. *Monatsschr Kinderheilkd* 1987; 135(3):128-134.
264. Janssen PJ, Brinkmann AO, Boersma WJ, van der Kwast TH. Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin- embedded human tissues after microwave pre-treatment. *J Histochem Cytochem* 1994; 42(8):1169-75.
265. Kimura N, Mizokami A, Oonuma T, Sasano H, Nagura H. Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. *J Histochem Cytochem* 1993; 41(5):671-8.
266. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. *Hypertension* 1995; 25(3):305-313.
267. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. *JAMA* 1978; 240(15):1607-1610.
268. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. *Am J Cardiol* 1971; 27(4):335-346.
269. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke: the Framingham Study. 1970. *JAMA* 1996; 276(15):1269-1278.
270. Ayala C, Steinberger E, Sweeney A et al. The relationship of serum androgens and ovulatory status to blood pressure in reproductive-age women. *Am J Hypertens* 1999; 12(8 Pt 1):772-777.

271. Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure- natriuresis in male spontaneously hypertensive rats. *Hypertension* 1998; 31(1 Pt 2):435-9.
272. Reckelhoff JF, Granger JP. Role of androgens in mediating hypertension and renal injury. *Clin Exp Pharmacol Physiol* 1999; 26(2):127-31.
273. Reckelhoff JF, Zhang H, Srivastava K, Granger JP. Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor. *Hypertension* 1999; 34(4 Pt 2):920-3.
274. Caplea A, Seachrist D, Daneshvar H, Dunphy G, Ely D. Noradrenergic content and turnover rate in kidney and heart shows gender and strain differences. *J Appl Physiol* 2002; 92(2):567-571.
275. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. *Cardiovasc Res* 2002; 53(3):688-708.
276. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. *N Engl J Med* 1999; 340(23):1801-1811.
277. James GD, Sealey JE, Muller F, Alderman M, Madhavan S, Laragh JH. Renin relationship to sex, race and age in a normotensive population. *J Hypertens Suppl* 1986; 4(5):S387-S389.
278. Kaplan NM, Kem DC, Holland OB, Kramer NJ, Higgins J, Gomez-Sanchez C. The intravenous furosemide test: a simple way to evaluate renin responsiveness. *Ann Intern Med* 1976; 84(6):639-645.
279. Ding Y, Sigmund CD. Androgen-dependent regulation of human angiotensinogen expression in KAP-hAGT transgenic mice. *Am J Physiol Renal Physiol* 2001; 280(1):F54-60.
280. Reckelhoff JF. Gender differences in the regulation of blood pressure. *Hypertension* 2001; 37(5):1199-208.
281. Jones TJ, Dunphy G, Milsted A, Ely D. Testosterone effects on renal norepinephrine content and release in rats with different Y chromosomes. *Hypertension* 1998; 32(5):880-885.
282. Guyton AC, Coleman TG, Cowley AV, Jr., Scheel KW, Manning RD, Jr., Norman RA, Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. *Am J Med* 1972; 52(5):584-594.
283. Callies F, Stromer H, Schwinger RH et al. Administration of testosterone is associated with a reduced susceptibility to myocardial ischemia. *Endocrinology* 2003; 144(10):4478-4483.

284. Nahrendorf M, Frantz S, Hu K et al. Effect of testosterone on post-myocardial infarction remodeling and function. *Cardiovasc Res* 2003; 57(2):370-378.